Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%

Published 06/06/2022, 12:27
Updated 06/06/2022, 13:10
© Reuters AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%

  • AstraZeneca Plc (NASDAQ: NASDAQ:AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy.
  • Financial Times wrote 'oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer."
  • Detailed results from the DESTINY-Breast04 Phase 3 trial showed that Enhertu reduced the risk of disease progression or death versus chemotherapy by 49% in patients with HER2-low metastatic breast cancer with HR-positive disease.
  • Related: Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer.
  • A median progression-free survival (PFS) of 10.1 months was seen in patients treated with Enhertu compared to 5.4 months with chemotherapy.
  • Results also showed a 36% reduction in the risk of death with Enhertu compared to chemotherapy in patients with HR-positive disease with a median overall survival (OS) of 23.9 months with Enhertu versus 17.5 months with chemotherapy.
  • Price Action: AZN shares are down 0.97% at $65.06 during the premarket session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.